mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook | Rothwell, Figg, Ernst & Manbeck, P.C.

In April of this year, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post we provide a 2021 year in review update on mRNA...

Related Keywords

Mexico ,Germany ,Paris ,France General ,France ,United Kingdom ,Suzhou ,Jiangsu ,China ,Nepal ,Austria ,Cambridge ,Cambridgeshire ,Indonesia ,Itiba ,Sichuan ,Switzerland ,Feng Zhang ,Shaanxi ,Chinese ,Swiss ,Roche Genentech ,Ozlem Tureci ,Abogen Biosciences ,Albert Bourla ,Ethris Planegg ,Rnaimmune Gaithersburg ,Metagenomi Emeryville ,Biosciences Medford ,Curevac Cvnco ,Ugur Sahin ,Glaxosmithkline ,National Institute Of Allergy ,National Institutes Of Health ,Gx In Technology Square ,Boehringer Ingelheim ,Novartis ,Pfizer ,Astrazeneca ,Kernal Biologics Inc ,Competitive Landscape ,Market Players ,Moderna Genomics ,Technology Square ,Federal Circuit ,National Institutes ,National Institute ,Infectious Diseases ,Neon Therapeutics ,Translate Bio ,Tidal Therapeutics ,Stabilized Non Immunogenic ,Strand Therapeutics ,Greenlight Biosciences ,Kernal Biologics ,Tiba Biotechnology ,Recode Therapeutics ,Menlo Park ,Stemirna Therapeutics ,Howard Hughes Medical ,Broad Institutes ,How Sanofi ,